In a Japanese Phase II study , the hepatitis C virus NS@/@A protease inhibitor simeprevir demonstrated potent antiviral activity and significantly improved sustained virologic response rates when added to peginterferon -@ a/ribavirin in treatment-nave patients infected with hepatitis C virus genotype @ .